Bristol-Myers Squibb has shored up manufacturing of its CAR-T therapies, tapping into capacity at contract manufacturer Cellares that will be used to supply patients in th
Cell and gene therapies are one of the most fast-moving and paradigm-shifting areas in pharmaceutical development today, bringing curative treatments to patients for the first time for cert
Cellares has just closed a major $255 million third-round financing that will be used to complete a highly automated facility in New Jersey for the production of cell ther
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year